Surgical Innovation Associates is an American medical technology developer, focusing on the development and commercialization of implantable and human absorbable medical devices in the field of plastic and reconstructive surgery. The company’s main product, DuraSorb®, was granted 510(k) marketing authorization by the FDA in 2018 for human soft tissue support. Integra LifeSciences announced today that it has entered into a definitive agreement to acquire Surgical Innovation Associates (SIA). Integra will acquire SIA for $50 million at closing, a deal scheduled to close by the end of the year. In addition, subject to customary adjustments to the purchase price, Integra will pay an additional $90 million when certain revenue targets and regulatory milestones are met.
This article is transferred from: https://www.itjuzi.com/merger/9519
This site is only for collection, and the copyright belongs to the original author.